Qualitative structure-metabolism relationships in the hydrolysis of carbamates

被引:61
作者
Vacondio, Federica [1 ]
Silva, Claudia [1 ]
Mor, Marco [1 ]
Testa, Bernard [2 ]
机构
[1] Univ Parma, Dipartimento Farmaceut, I-43100 Parma, Italy
[2] Univ Hosp Ctr CHUV, Dept Pharm, Lausanne, Switzerland
关键词
Carbamates; structure-property relationships (SPR); hydrolysis; metabolic stability; drug metabolism; IN-VITRO METABOLISM; HIV-1 PROTEASE INHIBITOR; HUMAN-LIVER-MICROSOMES; C-14 N-ETHOXYCARBONYL-3-MORPHOLINOSYDNONIMINE MOLSIDOMINE; LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; REVERSE-TRANSCRIPTASE INHIBITOR; ORAL FLUOROPYRIMIDINE CARBAMATE; MECHANISM-BASED INACTIVATION; HUMAN MORICIZINE METABOLISM; NUCLEAR-MAGNETIC-RESONANCE;
D O I
10.3109/03602531003745960
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aims of this review were 1) to compile a large number of reliable literature data on the metabolic hydrolysis of medicinal carbamates and 2) to extract from such data a qualitative relation between molecular structure and lability to metabolic hydrolysis. The compounds were classified according to the nature of their substituents ((ROCONRR2)-O-3-R-1), and a metabolic lability score was calculated for each class. A trend emerged, such that the metabolic lability of carbamates decreased (i.e., their metabolic stability increased), in the following series: Aryl-OCO-NHAlkyl >> Alkyl-OCO-NHAlkyl similar to Alkyl-OCO-N(Alkyl)(2) >= Alkyl-OCO-N(endocyclic) >= Aryl-OCO-N(Alkyl)(2) similar to Aryl-OCO-N(endocyclic) >= Alkyl-OCO-NHAryl similar to Alkyl-OCO-NHAcyl >> Alkyl-OCO-NH2 > Cyclic carbamates. This trend should prove useful in the design of carbamates as drugs or prodrugs.
引用
收藏
页码:551 / 589
页数:39
相关论文
共 262 条
[21]  
Birke FW, 2001, J PHARMACOL EXP THER, V297, P458
[22]   The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].
Blech, Stefan ;
Ebner, Thomas ;
Ludwig-Schwellinger, Eva ;
Stangier, Joachim ;
Roth, Willy .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399
[23]   Association between blood carisoprodol:: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers:: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? [J].
Bramness, JG ;
Skurtveit, S ;
Fauske, L ;
Grung, M ;
Molven, A ;
Morland, J ;
Steen, VM .
PHARMACOGENETICS, 2003, 13 (07) :383-388
[24]  
BRODIE RR, 1977, ARZNEIMITTEL-FORSCH, V27-1, P593
[25]   METABOLISM OF METHOCARBAMOL IN RAT, DOG, AND HUMAN [J].
BRUCE, RB ;
TURNBULL, LB ;
NEWMAN, JH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (01) :104-&
[26]   METABOLISM OF METAXALONE [J].
BRUCE, RB ;
TURNBULL, L ;
NEWMAN, J ;
PITTS, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1966, 9 (03) :286-&
[27]  
BRUGMANS JP, 1978, JAMA-J AM MED ASSOC, V217, P313
[28]   CEFOXITIN AND CEPHALOTHIN - ANTIMICROBIAL ACTIVITY, HUMAN PHARMACOKINETICS, AND TOXICOLOGY [J].
BRUMFITT, W ;
KOSMIDIS, J ;
HAMILTON.JM ;
GILCHRIST, JN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 6 (03) :290-299
[29]   Evaluation of capravirine as a CYP3A probe substrate: In vitro and in vivo metabolism of capravirine in rats and dogs [J].
Bu, Hai-Zhi ;
Zhao, Ping ;
Kang, Ping ;
Pool, William F. ;
Wu, Ellen Y. ;
Shetty, Bhasker V. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1593-1602
[30]   Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes [J].
Bu, Hai-Zhi ;
Zhao, Ping ;
Kang, Ping ;
Pool, William F. ;
Wu, Ellen Y. .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (11) :1798-1802